Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia (FVR)
Phase III, Random-Open, Clinical Trials on the Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia
Sponsor: Center for Research and Development of Health Resources and Services, National Institute of Health Research and Development (NIHRD), Indonesia
This PHASE3 trial investigates Covid19 and Infectious Disease and is currently completed. Center for Research and Development of Health Resources and Services, National Institute of Health Research and Development (NIHRD), Indonesia leads this study, which shows 7 recorded versions since 2020 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Apr 2023 — Jul 2024 [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
Nov 2021 — Apr 2023 [monthly]
Recruiting PHASE3
Status: Suspended → Recruiting
-
Feb 2021 — Nov 2021 [monthly]
Suspended PHASE3
Status: Recruiting → Suspended
▶ Show 2 earlier versions
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE3
First recorded
Oct 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Center for Research and Development of Health Resources and Services, National Institute of Health Research and Development (NIHRD), Indonesia
- Ina-Respond
For direct contact, visit the study record on ClinicalTrials.gov .